Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection

Yu-Fen Tsai,Yi-Chang Liu,Ching-I Yang,Tzer-Ming Chuang,Ya-Lun Ke,Tsung-Jang Yeh,Yuh-Ching Gau,Jeng-Shiun Du,Hui-Ching Wang,Shih-Feng Cho,Chin-Mu Hsu,Pey-Fang Wu,Ching-I Huang,Chung-Feng Huang,Ming-Lung Yu,Chia-Yen Dai,Hui-Hua Hsiao
DOI: https://doi.org/10.3390/jpm11090844
IF: 3.5083
2021-08-27
Journal of Personalized Medicine
Abstract:Background: Hepatitis C virus (HCV) in diffuse large B-cell lymphoma (DLBCL) is associated with a higher prevalence and distinctive clinical characteristics and outcomes. Methods: A retrospective analysis of adult DLBCL patients from 2011 to 2015 was studied. Results: A total of 206 adult DLBCL were enrolled with 22 (10.7%) HCV-positive patients. Compared to HCV-negative patients, the HCV-positive group had a poor performance status (p = 0.011), lower platelet count (p = 0.029), and higher spleen and liver involvement incidences (liver involvement, p = 0.027, spleen involvement, p = 0.026), and they received fewer cycles of chemotherapy significantly due to morbidity and mortality (p = 0.048). Overall survival was shorter in HCV-positive DLBCL (25.3 months in HCV-positive vs. not reached (NR), p = 0.049). With multivariate analysis, poor performance status (p < 0.001), advanced stage (p < 0.001), less chemotherapy cycles (p < 0.001), and the presence of liver toxicity (p = 0.001) contributed to poor OS in DLBCL. Among HCV-positive DLBCL, the severity of liver fibrosis was the main risk factor related to death. Conclusion: Inferior survival of HCV-positive DLBCL was observed and associated with poor performance status, higher numbers of complications, and intolerance of treatment, leading to fewer therapy. Therefore, anti-HCV therapy, such as direct-acting antiviral agents, might benefit these patients in the future.
medicine, general & internal,health care sciences & services
What problem does this paper attempt to address?